Chris Carlson
Executive Vice President, Research, Corporate Development, Corporate Strategy and Intuitive VenturesIntuitive Surgical
Medical DevicesView Profile →Senior Vice President, Investor Relations · Zimmer Biomet Holdings
David DeMartino is senior vice president of investor relations at Zimmer Biomet Holdings. He previously worked in healthcare investment banking, equity research and asset management and served as chief strategy officer of Nyxoah.
Last reviewed: Nov 4, 2026
Senior Vice President, Investor Relations
Zimmer Biomet Holdings
Last Reviewed: November 4, 2026
David DeMartino is senior vice president of investor relations at Zimmer Biomet Holdings. He previously worked in healthcare investment banking, equity research and asset management and served as chief strategy officer of Nyxoah.
DeMartino began his career in Deutsche Bank’s healthcare investment banking group. He subsequently moved into sell-side equity research, initially covering healthcare facilities at Deutsche Bank and then medical devices at Credit Suisse.
His investing career included serving as a portfolio manager at DNB Asset Management and holding senior analyst positions at Velan Capital, Citadel and Pura Vida Investments. His research covered medical devices, biotechnology and healthcare technology. At Pura Vida, he worked on investments in private companies as well as publicly traded businesses.
Before joining Zimmer Biomet, DeMartino served as chief strategy officer of Nyxoah, a medical technology company developing treatments for obstructive sleep apnea. This operating-company assignment followed his work across investment banking, research and asset management.
DeMartino became Zimmer Biomet’s senior vice president of investor relations on September 9, 2024, reporting to chief executive Ivan Tornos. He leads the company’s investor relations strategy and its relationships with the investment and financial community.
DeMartino earned a BA in economics from Washington and Lee University.